Auction/sales now in progress
[Looking for the now archived free
BIOPHARMA®: Biopharmaceutical
Products in the U.S. and European Markets databases?]
If you already recognize the high value of this IP, you can skip down to the "Bottom Line" section.
'Biopharma' is a >$1 trillion revenue/year industry using the now predominant broad definition; and is a >$400
billion/year subset of the pharmaceutical/drug industry using the classic definition.
In the next few years,
the 'Pharma(ceutical)'
industry will genuinely become the 'Biopharma(ceutical)' industry as biopharmaceutical (using the classic biotech-grounded
defintion) R&D and product revenue top that of chemically-derived/synthetic
pharmaceuticals.
With this, 'biopharma(ceutical)' will come to fully
replace 'pharma(ceutical)' in common usage; surely assisted by
the global pharmaceutical industry, long publicly claiming to be
'biopharmaceutical.'
Most of the world's leading (bio)pharmaceutical companies and trade groups have
already switched to using 'biopharmaceutical' to refer to and
(re)brand themselves, their products and the industry.
PhRMA has been prominently
citing its members as and using the tagline "America's Biopharmaceutical Companies" now since 2005 (17 years);
and "The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the biopharmaceutical industry operating in
Europe." Along with the switch to using 'biopharma(ceutical),' 'pharma(ceutical)' and 'drug' are
increasingly evoking negative perceptions and becoming legacy/dated, deprecated, simply no longer used.
For example, try to find any use by PhRMA, e.g., its current Website,
"flagship publication" and related "Industry Toolkits."
As with "pharma," the word "biopharma" has universal recognition and is used both as an adjective (e.g., biopharma R&D, products, companies, etc.) and a proper noun
(e.g., "Biopharma," referring to the industry).
Google retrieved 16.9 million entries for the word "biopharma" (in quotes, no truncation) and 74.4 million for "biopharma" (truncated) on Sept. 19 (these nos. vary daily).
Use of "Biopharmas" to refer to companies is a new trend e.g., Google retrieves >30,000 entries.
There are >600 publicly traded companies in the U.S. with
"biopharma" in their name (SEC); and a total of >2,000 "biopharma" companies in the U.S. and
~4,000 worldwide (D&B). There are >2,650 "biopharma" (no truncation) company entries in Cruchbase and >800 in LinkedIn.
Over 4,150 domain names contain, >1,100 names
start with and >2,500 end with "biopharma."
BIOPHARMA Domain + Trademark = BIOPHARMA Internet Dominance: Top-level domain and exact-match U.S. trademark ownership, a potent and rare combination,
will provide your organization with exclusive and unbeatable "BIOPHARMA" Internet presence and
branding opportunities!
How much is it worth to your organization to be
recognized as a (or the) leading 'Biopharma' industry organization and/or be the top-level/first-used industry information source?
For example:
There will be no better top-level industry-defining IP available, e.g., the only potential competition,
"pharma.com," is tainted, used by opioid epidemic-associated Purdue Pharma and being sold as part of its
bankruptcy proceedings (and otherwise, who wants to be "pharma" vs. "biopharma?")
Value:
To perhaps(???) put the current commercial value of this IP in some context, the 'closest' (industry top-end-type)
published domain sales (in current $) include "drugs.com" which sold for >$1.2 million in 1999;
"pharmacy.com" for $2.9 million in 2008 and; Rx.com for $1 million in 2019.
BIOPHARMA.com surely has comparable or more and broader
utility and value than
such legacy 'drug' and 'pharmaceutical' transactional (all used for online prescription sales) domains.
Good "brandable" (blank slate) single word .com domains now commonly sell for this much, often more.
In contrast, "BIOPHARMA" is a truly exemplary established single word industry-defining, world-wide recognized brand with the
highest value and good will among all industries.
As intangible assets and corporate investments, the domains and trademark
are solid and reliable.
Can you even imagine any loss of value or downsides to owning this IP?
Most likely you are already envisioning $millions/year in benefits use of this IP could
provide your organization.
Ownership, even without use, is also an excellent option, whether as a high return investment or
for strategic denial of use (e.g., Abbvie purchased "biosimilars.com" from me 9 years ago
and has never used it). Your prudent use will add further to your domain's value.
Bottom Line:
'BIOPHARMA' is simply the top-most and best domain name, brand, trademark, corporate identity, etc. for the world's most
important, high tech, profitable and image-conscious industry!
"BIOPHARMA" has replaced (or is fast replacing) "pharma(ceutical)" and "drug," particularly when seeking to project a
positive, high (bio)tech, etc. image.
Biopharma.com and .org combined with the BIOPHARMA® trademark are truly dominant and enviable top-level
industry-defining IP and branding opportunities - embodying the modern biopharmaceutical
industry and the
inestimable good will it has earned.
Background: 'Biopharma(ceutical):'
1) Within the industry, science, etc. this term often still retains its
original/classic biotechnology-grounded definition involving pharmaceuticals
manufactured using biotechnology (living organisms), with 'biopharma(ceutical)' a subset of 'pharma(ceutical).'
2) In the past decade-plus with push from industry, "biopharma(ceutical)" has become (or soon enough will be)
the preferred popular/common and industry's-own term for the
global pharmaceutical industry and its products, particularly where desiring to project a positive image.
'Biopharma(ceutical)' has or is replacing 'pharma(ceutical)' in common and industry use, much as
'pharma(ceutical)' replaced use of 'drug' in the 1970s/80s.
Or the term sometimes refers more to or implies only innovative/R&D-intensive (bio)pharmaceuticals and
companies, as often used by
the largest R&D-intensive companies and their trade groups.
[This broad industry Pharma(ceutical) → Biopharma(ceutical) renaming/rebranding trend is nothing new. See a related Nature Biotechnology article, "(Re)Defining Biopharmaceutical," I authored
~15 years ago].
a) Brand your Web site, company, trade group, products, technologies, services, information resources, etc. as "BIOPHARMA." 
Your company might even become "BIOPHARMA.com Inc." or even "Biopharma Inc."
b) Be the leading source for information and promote your image and views
about the biopharmaceutical industry;
its products, technologies, public affairs, etc.; and/or otherwise
c) Greatly improve the impact and cost-effectiveness of your
public relations, marketing, advertising, lobbying, etc.
Such a prominent domain/trademark is its own perpetual advertising campaign.
The utility, impact, benefits and cost-effectiveness of a 'BIOPHARMA' domain/trademark/branding will surely be much higher
than your usual episodic and transitory advertising, marketing, public relations, lobbying, efforts.
And for a 1-time purchase at a fair price (open for bids now), this IP can remain yours forever.
  Biopharma.com has received a "fair market"
appraisal of
$1,000,000 (without trademark; for domain investor/reseller, not the end-user market)
from AccurateAppraisals.com
(M. Mann, #1 owner of domains, >300,000].
Contact the owner:
President Biotechnology Information Institute Rockville, MD 20851 E-Mail: domains@biopharma.com Phone: 301-424-0255 |